Treatment of DM2 to-day. Should we change priorities? Conclusions based on recent clinical studies
https://doi.org/10.14341/2072-0351-5716
Abstract
This work is devoted to the analysis of results of recent clinical studies. It is argued that the absence of close association between normalized glycemiaand reduced incidence of cardiovascular disorders may be due to both relatively short duration of observations and possible effect of co-factors (e.g. hypoglycemia/drug interaction, etc.). Some results suggest the necessity of multifactor approach to the treatment of DM2 especially for the reductionof cardiovascular mortality or prevention of vascular catastrophes. Sulphonylurea derivatives are regarded as putative risk factors of hypoglycemiaor vascular disorders. A number of publications are reviewed in which glibenclamide was shown to be safe in terms of risk of myocardial infarction.
References
1. Nissen S.E., Tardif J.C., Nicholls S.J. et al. Effect of torcetrapib on the progression of coronary atherosclerosis // N. Engl. J. Med. - 2007. - 356. - 1304-1316.
2. Anderson G.I., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial // JAMA. - 2004. - 291. - 1701-1712.
3. Greenland P., Lloyd-Jones D. Critical lessons from ENHANCE trial. JAMA. - 2008. - 299(8). - 953-955.
4. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes // N. Engl. J. Med. - 2007. - 356. - 2457-2471.
5. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - 358. - 1547- 1559.
6. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus // N. Engl. J. Med. - 993. - 329. - 977-986 .
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 352. - 837-853.
8. Krolewski A.S., Warram J.H., Valsania P., Martin B.C., Laffel L.M., Christlieb A.R. Evolving natural history of coronary heart disease in diabetes mellitus // Am. J. Med. - 1991. - 90. - 56-61.
9. Laakso M., Lehto S. Epidemiology of macrovascular disease in diabetes // Diabetes Rev. - 1997. - 5. - 294-315.
10. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. Jr., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H. Jr., Probstfield J.L., Simons-Morton D.G., Friedewald W.T.: Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - 2545- 2559.
11. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M, Cooper M., Glas-ziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - 2560-2572.
12. Skyler S., Bergenstal R., Bonow R. et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials //Diabetes Care. - 2009. - 32(1). - 187-192.
13. hppt://www.americangeriatrics.org.
14. Gaede P. Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - P.580-591.
15. hppt://www.dtu.ox.ac.uk.
16. Nathan D., Buse J.B., Davidson M.B. et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care. - 2006. - 29(8). - P. 1963-1972.
17. Kahn S.E. et al. For the ADOPT stydy group: Glycemic Durability of rosiglitazone, Metformin or Glyburide / N. Engl. J. Med. - 2006. - 355. - P. 2427-2443.
18. Miller D.R. and Podach L. Longiditual Approaches to Evaluate Health Care Quality and Outcomes: The veterans Health Administration Diabetes Epidemiology Cohorts.//Diabetes Sci Technol . - 2008. - 2 (1). - P. 24-32
Review
For citations:
Zilov A.V. Treatment of DM2 to-day. Should we change priorities? Conclusions based on recent clinical studies. Diabetes mellitus. 2009;12(4):108-113. (In Russ.) https://doi.org/10.14341/2072-0351-5716
Views:
991
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
